Drug, Device Companies Urge Stronger Value-Based Payment Protections


Ankur Goel said greater use of a value-based rather than fee-for-service healthcare model leaves the drug and device anti-kickback safe harbors ripe for change, since they reflect the traditional model of more reimbursements for physicians with higher volume. “I expect the OIG [Office of Inspector General] will indeed take steps to modernize the safe harbors to align with the direction of payment in the health-care system,” Mr. Goel predicted.